Overview Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Status: Completed Trial end date: 2019-02-28 Target enrollment: Participant gender: Summary The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality. Phase: Phase 3 Details Lead Sponsor: Asahi Kasei Pharma America Corporation